PLCPRF5_LIVER
HCC · Hepatocellular Carcinoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- HCC
- cancer_type_detailed
- Hepatocellular Carcinoma
- subtype
- —
- cancer_type
- HCC
- ccle_sample_id
- PLCPRF5_LIVER
- synthetic_from_ccle
- true
- display_name
- PLC/PRF/5
- ccle_lineage
- liver
- ccle_lineage_subtype
- hepatocellular_carcinoma
- oncotree_code
- HCC
- cancer_type_detailed
- Hepatocellular Carcinoma
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COAGULATION+0.685
- XENOBIOTIC_METABOLISM+0.589
- TNFA_SIGNALING_VIA_NFKB+0.570
- UV_RESPONSE_UP+0.458
- CHOLESTEROL_HOMEOSTASIS+0.430
- ANGIOGENESIS+0.354
- BILE_ACID_METABOLISM+0.351
- PROTEIN_SECRETION+0.347
- UNFOLDED_PROTEIN_RESPONSE+0.346
- ADIPOGENESIS+0.316
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.074
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.061
- G2M_CHECKPOINT-0.048
- INTERFERON_GAMMA_RESPONSE-0.044
- ALLOGRAFT_REJECTION-0.044
- UV_RESPONSE_DN-0.036
- HEDGEHOG_SIGNALING-0.033
- HEME_METABOLISM-0.023
- WNT_BETA_CATENIN_SIGNALING-0.017
- KRAS_SIGNALING_UP-0.001
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AD9F-TTM1-A-1-1-R-A542-39 | — | C | 0.808 |
| 2 | AUR-AFEC-TTM4-A-1-1-R-A742-41 | — | C | 0.789 |
| 3 | HUH7_LIVER | HCC | — | 0.781 |
| 4 | SNU878_LIVER | HCC | — | 0.771 |
| 5 | SRR6013485 | — | cohortA4 | 0.768 |
| 6 | MNG688 | — | — | 0.759 |
| 7 | AUR-AERY-TTM1-A-1-1-R-A742-41 | — | C | 0.747 |
| 8 | ULC1887T_S73 | — | cohortA4 | 0.731 |
| 9 | TCGA-39-5039-01A-01R-1443-07 | — | cohortSQ1 | 0.725 |
| 10 | 20060039.TNBC | — | C | 0.725 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COAGULATION | 0.685 | Binimetinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.589 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.570 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.458 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.430 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.354 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.351 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.347 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.346 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.316 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.294 | Inavolisib | — uncovered |
| PEROXISOME | 0.263 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.258 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.244 | Cobimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.236 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.233 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.230 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.229 | Inavolisib | — uncovered |
| HYPOXIA | 0.222 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.192 | Inavolisib | — uncovered |